Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.40 |
| ▸ | HPGD | P15428 | 10/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936490 | 0.84 | CYP3A4 (0.40) | CYP3A4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30076358 | 0.83 | CYP3A4 (0.41) | CYP3A4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9937539 | 0.83 | CYP3A4 (0.41) | CYP3A4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9937775 | 0.80 | HSD17B10 (0.41) | CYP3A4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9938505 | 0.79 | HRH3 (0.38) | CYP3A4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2674207 | 0.78 | HDAC1 (0.45) | CYP3A4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL25233723 | 0.78 | CYP3A4 (0.60) | CYP3A4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2396728 | 0.73 | CYP3A4 (0.45) | CYP3A4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1113999 | 0.73 | PIK3CA (0.52) | CYP3A4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL25281454 | 0.73 | CNR2 (0.42) | SMN1; SMN2HDAC1HRH3NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9546182-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. | 2017-01-17 | — | — | US | disclosed |
| EP-3053925-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2813506-B1 | Tricyclic PI3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-20150079081-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2813506-A1 | Tricyclic PI3K inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2014-12-17 | — | — | EP | disclosed |
| EP-2651951-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8883799-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2651951-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| WO-2012082997-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA-ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | CYP3A4 1190/4885KDM4E 2156/4885ALDH1A1 4549/4885 |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | CYP3A4 1099/4885KDM4E 3330/4885ALDH1A1 4455/4885 |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | CYP3A4 1190/4885KDM4E 2156/4885ALDH1A1 4549/4885 |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | CYP3A4 1099/4885KDM4E 3330/4885ALDH1A1 4455/4885 |
| US-20150079081-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | CYP3A4 1190/4885KDM4E 2156/4885ALDH1A1 4549/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | CYP3A4 2620/4885KDM4E 3811/4885ALDH1A1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.